Champlain Investment Partners LLC Lowers Stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Champlain Investment Partners LLC lessened its stake in PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 29.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 456,930 shares of the company’s stock after selling 193,363 shares during the period. Champlain Investment Partners LLC owned 0.88% of PROCEPT BioRobotics worth $36,792,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Signaturefd LLC increased its position in shares of PROCEPT BioRobotics by 26.7% during the fourth quarter. Signaturefd LLC now owns 689 shares of the company’s stock worth $55,000 after acquiring an additional 145 shares during the period. Naviter Wealth LLC raised its position in PROCEPT BioRobotics by 6.0% during the 4th quarter. Naviter Wealth LLC now owns 3,089 shares of the company’s stock valued at $249,000 after purchasing an additional 176 shares in the last quarter. Amundi lifted its holdings in shares of PROCEPT BioRobotics by 0.9% in the 4th quarter. Amundi now owns 20,143 shares of the company’s stock worth $1,742,000 after buying an additional 183 shares during the period. Arizona State Retirement System grew its position in shares of PROCEPT BioRobotics by 1.5% during the 4th quarter. Arizona State Retirement System now owns 14,285 shares of the company’s stock worth $1,150,000 after buying an additional 218 shares in the last quarter. Finally, KRS Capital Management LLC increased its stake in shares of PROCEPT BioRobotics by 0.5% during the fourth quarter. KRS Capital Management LLC now owns 46,455 shares of the company’s stock valued at $3,741,000 after buying an additional 225 shares during the period. Institutional investors own 89.46% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on the stock. Truist Financial dropped their target price on shares of PROCEPT BioRobotics from $90.00 to $70.00 and set a “buy” rating on the stock in a report on Friday, April 11th. Morgan Stanley dropped their price objective on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, PROCEPT BioRobotics has an average rating of “Moderate Buy” and a consensus price target of $91.43.

PROCEPT BioRobotics Stock Up 0.4 %

NASDAQ:PRCT opened at $53.03 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The stock has a market capitalization of $2.91 billion, a P/E ratio of -27.19 and a beta of 1.09. The company’s 50-day simple moving average is $59.75 and its 200-day simple moving average is $75.01. PROCEPT BioRobotics Co. has a fifty-two week low of $47.04 and a fifty-two week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its earnings results on Tuesday, February 25th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The firm had revenue of $68.24 million during the quarter, compared to analyst estimates of $66.79 million. PROCEPT BioRobotics had a negative net margin of 50.07% and a negative return on equity of 38.57%. On average, equities analysts anticipate that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Reza Zadno sold 5,475 shares of the business’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the sale, the chief executive officer now owns 173,070 shares of the company’s stock, valued at approximately $9,875,374.20. The trade was a 3.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Kevin Waters sold 733 shares of the company’s stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the transaction, the chief financial officer now owns 107,991 shares in the company, valued at $6,161,966.46. The trade was a 0.67 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 6,455 shares of company stock valued at $368,322 in the last ninety days. Corporate insiders own 17.40% of the company’s stock.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).